Literature DB >> 16255761

Immune tolerance to hepatitis C virus acquired during engraftment of bone marrow transplant.

A Godkin1, P Openshaw, H C Thomas.   

Abstract

The CD4+ T-cell response appears to be important for clearance of hepatitis C virus (HCV) in the majority of individuals. We have recently described a series of human leucocyte antigen (HLA)-DR11-restricted T-cell epitopes derived from HCV proteins which enables distinct populations of memory CD4+ T cells to be detected and counted in all nonviraemic HCV subjects. We examined the case of an HLA-DR11+ recipient of a haematopoietic stem-cell transplant who was concurrently infected with HCV from an HLA-DR11+ donor sibling. An acute HCV hepatitis developed and was treated with type I interferon. After successful viral clearance, the recipient demonstrated a selective lack of HCV epitope-specific CD4+ T cells and absence of serological responses compared with the treated donor. The recipient had no evidence of any nonspecific immunosuppression. The subsequent effects of concurrent infection during immune reconstitution are not known in adult humans, but data from murine models suggest this can lead to a skewing of the T-cell repertoire because of thymic selection. From the above observations, it is plausible that the introduction of foreign viral antigen into the thymus may lead to subsequent acquired central tolerance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16255761     DOI: 10.1111/j.1365-2893.2005.00627.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  2 in total

Review 1.  Rapid innate control of antigen abrogates adaptive immunity.

Authors:  Thomas P I Pembroke; Awen M Gallimore; Andrew Godkin
Journal:  Immunology       Date:  2013-04       Impact factor: 7.397

2.  Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+ T-cell immunity.

Authors:  Tom Pembroke; Ian Rees; Kathleen Gallagher; Emma Jones; Paul Mizen; Timur Navruzov; Andrew Freedman; Ceri Fielding; Ian R Humphreys; Eddie C Y Wang; Awen M Gallimore; Andrew Godkin
Journal:  Eur J Immunol       Date:  2012-08-06       Impact factor: 5.532

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.